Structural basis for substrate recognition and inhibition of human glucose-6-phosphate transporter SLC37A4 Authors: Hui Li, Xiaomin Peng, Yuwen Huang, Wencheng Wu, Nan Li, Ziqi Cheng, Xuepeng Wei, Richard Hodge, Richard Hodge, Richard Hodge, Richard Hodge Published: 2026 ABSTRACT Glucose 6 phosphate (G6P) homeostasis is essential for maintaining blood glucose levels and coordinating anabolic and catabolic pathways. A key step in this process is the delivery of G6P into the endoplasmic reticulum (ER), where it is hydrolyzed by glucose 6 phosphatase to glucose and inorganic phosphate (Pi). This transport step is carried out by the ER carrier SLC37A4 (also known as the G6P transporter, G6PT), which imports G6P into the ER lumen while exporting Pi to the cytosol, and loss-of-function mutations in SLC37A4 cause glycogen storage disease type Ib. Despite its central role in G6P homeostasis, how SLC37A4 recognizes G6P and couples its transport to Pi antiport has remained unclear. Here we report cryo-electron microscopy structures of human SLC37A4 in three states: the apo form at 2.8 Å resolution, a G6P-bound state at 3.2 Å resolution and a chlorogenic acid (CHA) bound state at 3.3 Å resolution. SLC37A4 adopts the canonical Major Facilitator Superfamily fold and harbors a central, positively charged cavity that accommodates anionic substrates. In the G6P-bound structure, SLC37A4 adopts an outward-open conformation facing the ER lumen, in which G6P binds to the electropositive pocket. In the CHA-bound structure, SLC37A4 adopts an inward-facing conformation, with CHA bound at a cytosolic site that locks the transporter in an arrested state and prevents the conformational transitions required for G6P/Pi exchange. Combined with thermostability and transport-based analyses of G6P binding and disease variants, these structures support a rocker switch mechanism in which electrostatic neutralization of the central positively charged cavity by anionic substrate drives the conformational changes underlying G6P/Pi exchange. Together, these findings define the structural basis of G6P/Pi exchange by SLC37A4, provide a molecular rationale for pathogenic mutations in glycogen storage disease type Ib, and provide a framework for targeting SLC37A4 to modulate G6P homeostasis. Introduction Glucose-6-phosphate (G6P) serves as a critical metabolic hub at the intersection of several major pathways, seamlessly linking glycolysis, the pentose phosphate pathway, and glycogen metabolism to maintain cellular energy balance [1–3]. Following cellular uptake, free glucose is immediately phosphorylated to G6P by the rate-limiting enzymes hexokinase and glucokinase, a phosphorylation event that effectively traps glucose within the cell [4–6]. While cytosolic metabolism allows G6P to direct carbon flux toward immediate energy production, redox balance, or biosynthesis, G6P homeostasis crucially depends on its transport into the endoplasmic reticulum (ER) lumen to support systemic glucose release. This translocation is mediated by SLC37A4 (also known as the glucose-6-phosphate transporter, or G6PT), which functions as an obligate antiporter, moving cytosolic G6P into the ER while simultaneously exporting inorganic phosphate (Pi) back to the cytosol [7,8]. Once inside the ER, G6P is hydrolyzed by glucose-6-phosphatase into glucose and Pi, which are then returned to the cytosol to enable glucose efflux into the circulation. The physiological necessity of SLC37A4/G6PT is illustrated by the consequences of its failure, particularly in the context of glycogen storage disease type Ib (GSD Ib). Dysfunction of SLC37A4 disrupts the delicate transport process, leading directly to this rare, autosomal recessive disorder [9–12]. Despite the critical role of SLC37A4 in human physiology and disease, the molecular mechanisms by which it selectively recognizes G6P, coordinates the precise exchange of G6P and Pi, and undergoes the necessary conformational transitions for transport have historically remained poorly understood. In this study, we report high-resolution cryo-electron microscopy (cryo-EM) structures of human SLC37A4 in three distinct functional states: the apo state, the G6P-bound state, and an inhibitor-bound state complexed with chlorogenic acid (CHA). By integrating these structural insights with thermostability-shift and transport assays characterizing G6P binding and function, we elucidate the molecular mechanism of substrate recognition and conformational cycle underlying G6P transport, demonstrating how the transporter navigates between inward- and outward-facing conformations to facilitate the exchange of G6P and Pi. The CHA-bound structure further reveals a cytosolic inhibitory site and defines how CHA prevents the conformational transitions required for transport. Ultimately, this work provides a comprehensive structural framework for understanding SLC37A4 function, offers a molecular rationale for pathogenic mutations in GSD Ib, and lays the foundation for therapeutic development targeting SLC37A4. Results Overall structure of SLC37A4 To elucidate the structural basis of G6P transport, we expressed SLC37A4 in HEK293 cells, purified the protein in the detergent lauryl maltose neopentyl glycol (LMNG) and determined its structure using single particle cryo-EM (S1 Fig). Although 2D classification revealed the presence of both monomeric and dimeric species, iterative rounds of heterogeneous refinement enabled isolation of the monomeric particles and yielded a reconstruction of the apo state at 2.8 Å resolution (S2 Fig and Table 1). The SLC37A4 structure exhibits the canonical fold of the Major Facilitator Superfamily (MFS), comprising 12 transmembrane helices (TMs). These helices are organized into two distinct domains, an N-terminal domain (NTD; TM1–6) and a C-terminal domain (CTD; TM7–12), which are connected by a highly flexible cytosolic loop. Because of this flexibility, the residues 202–211 were not resolved in the cryo-EM map and were omitted from the final model. Together, the NTD and CTD display the characteristic pseudo 2-fold symmetry of the MFS family (Fig 1A–1C). 10.1371/journal.pbio.3003833.t001Table 1Cryo-EM data collection, refinement, and validation statistics.SLC37A4-apo(EMDB-67847)(PDB 21NQ)SLC37A4-G6P(EMDB-67869)(PDB 21OR)SLC37A4-CHA(EMDB-67846)(PDB 21NP) Data collection and processing Magnification215,000215,000215,000Voltage (kV)300300300Electron exposure (e−/Å2)505050Defocus range (μm)0.8-1.60.8-1.60.8-1.6Pixel size (Å)0.5780.5780.578Symmetry imposedC1C1C1Initial particle images (no.)5,769,2725,093,1644,959,911Final particle images (no.)115,232149,88082,953Map resolution (Å)2.83.23.3FSC threshold0.1430.1430.143Map resolution range (Å)2.7-3.52.8-4.02.8-4.0 Refinement Initial model used (PDB code)AlphafoldAlphafoldAlphafoldModel resolution (Å)2.93.33.5FSC threshold0.50.50.5Model compositionNon-hydrogen atoms3,1593,1753,244Protein residues414414422Ligands011B factors (Å2)Protein128.08119.11105.31Ligand–200.24107.84R.m.s. deviationsBond lengths (Å)0.0030.0030.004Bond angles (°)0.6710.7540.669ValidationMolProbity score1.481.841.89Clashscore6.3314.658.96Poor rotamers (%)1.50.60.9Ramachandran plotFavored (%)98.0597.0794.05Allowed (%)1.952.935.95Disallowed (%)000 Cryo-EM data collection, refinement, and validation statistics. Overall structure of human SLC37A4 in the apo state. (A) Cryo-EM density map of SLC37A4-apo viewed along the membrane plane. The protein density is shown in green and the detergent micelle shown in transparent gray. (B) Cartoon representation of SLC37A4 structure in the same membrane plane orientation as in a. N-terminal domain NTD is shown in yellow and C-terminal domain CTD is shown in cyan, individual transmembrane helices are numbered. The dashed line indicates an unresolved cytosolic loop between residues 201 and 212 that connects TM6 and TM7, linking the NTD and CTD. (C) View of SLC37A4 from the ER-lumen side along membrane normal, obtained by a 90° rotation of the model in b, showing the arrangement of the NTD and CTD. (D) Overall structure of SLC37A4 in the orientation in a, highlighting 4 positively charged residues in the putative substrate-binding pocket. (E) Cutaway view in the orientation of a, showing a slice through the putative substrate binding pocket. (F) Electrostatic surface representation of SLC37A4 viewed from the same orientation in c, ER-lumen side along the membrane normal, showing the putative substrate-binding pocket and the location of R28, K29, K64 and K240. In the apo state, SLC37A4 adopts a wide outward-open conformation facing the ER lumen. This conformation likely represents the state for either G6P release into the lumen or subsequent loading of Pi, corresponding to the stage of the transport cycle prior to resetting to the cytosol-facing state (Fig 1B and 1C). Electrostatic potential surface analysis reveals a positively charged cavity in SLC37A4, primarily generated by four key basic residues: R28 and K29 on TM1, K64 on TM2, and K240 on TM7(Fig 1C). Given that both G6P and Pi are negatively charged, we speculate that this positively charged pocket is responsible for substrate binding (Fig 1D–1F). Structure of SLC37A4 bound to G6P substrate To elucidate the molecular basis of substrate recognition, we determined the structure of SLC37A4 in the presence of G6P at 3.2 Å resolution (S3 Fig and Table 1). Superposition of the apo and G6P-bound structures shows that the overall fold is nearly identical, with a root-mean-square deviation (RMSD) of 0.29 Å between Cα atoms, indicating that substrate binding does not induce a global conformational change (Fig 2A and 2B). Both structures were captured in an outward-facing conformation, which appears to be stabilized by extensive NTD-CTD interactions on the cytosolic side (Fig 2D). Hydrogen bonds and salt bridges are formed between D72 on TM2 and T364 on TM11, R126 on TM4 and T354 on TM10, as well as T136 on TM5 and D285 on TM8. These contacts likely stabilize the NTD and CTD in an arrangement that keeps the transporter open to the ER lumen (Fig 2D). Structural basis of G6P recognition by SLC37A4. (A) Superposition of the SLC37A4 apo state (gray) and the G6P-bound state (NTD in yellow, CTD in cyan). The structures are shown as cylindrical cartoons viewed along the membrane plane. The bound G6P molecule is shown as red sticks in the central cavity. The dashed line indicates an unresolved cytosolic loop between residues 201 and 212 that connects TM6 and TM7, linking the NTD and CTD. (B) View of the superposed apo and G6P-bound structures from the ER-lumen side along the membrane normal, highlighting G6P and nearby residues R28, K29, Y60, K64, F237 and K240. (C) Cryo-EM density of the bound G6P molecule, with a contour level of 3σ. (D) View of the interface between the N- and C-terminal domains from the cytosolic side along the membrane normal, showing gating residues at the domain interface, including D72, R126, T136, D285, T354 and T364. (E) Electrostatic surface representation of SLC37A4 viewed from the same orientation in b. (F) Two-dimensional schematic of the G6P-binding sites, depicting hydrogen-bond interactions between G6P and K64, as well as hydrophobic contacts with F237 and Y60. (G) GFP-based thermostability assay showing G6P-induced changes in melting temperature (ΔTm) for wild type (WT) SLC37A4 and G6P-binding–site mutants (R28A, R28C, R28H, K29A, Y60A, K64A, K240A). Bars represent mean ± s.d. of measurements performed at least in triplicate. The underlying data for this figure can be found in S1 Data. (H) Relative [13C6]G6P uptake for WT and mutant SLC37A4. Bars represent mean ± s.d. of measurements performed at least in triplicate. The underlying data for this figure can be found in S1 Data. Closer inspection of the positively charged cavity revealed additional density not present in the apo map (Figs 2C and S4). This density is located within the central cavity below the NTD-CTD interface (Fig 2A and 2B). This density lies within about 3 Å of K64 on TM2, and is also closely surrounded by R28 and K29 on TM1, Y60 on TM2 and F237 and K240 on TM7 (Fig 2B). Based on the size, shape, and the local chemical environment, we tentatively assigned this feature as the bound G6P substrate. The phosphate group of G6P forms hydrogen bonds with the side chain of K64, whereas the sugar moiety forms hydrophobic interactions with bulky residues Y60 and F237 (Fig 2B and 2F). Collectively, these residues define a positively charged, polar-aromatic pocket (Fig 2E) that accommodates the phosphate and glucose moieties of G6P. We generated alanine mutants and assessed their thermostability to validate the roles of these potential substrate-binding residues. The observed reduction in thermal shift upon substrate addition confirmed that these residues are indeed responsible for substrate binding (Figs 2G and S5). Furthermore, despite comparable protein expression levels across all mutants (S6 Fig), these mutations significantly impaired G6P transport activity, as demonstrated by a relative [13C6]G6P uptake assay (Fig 2H). Notably, the naturally occurring disease-related mutations R28C and R28H also exhibited severe defects in both substrate binding and transport (Fig 2G and 2H). Structure of SLC37A4 bound to inhibitor CHA Previous studies identified CHA and its analog as potent inhibitors of SLC37A4 [13–16]. Hypothesizing that inhibitor binding might trap the transporter in a distinct conformational state, allowing us to capture an alternative stage of the transport cycle and elucidate the structural basis of G6P transport, we sought to determine the structure of the CHA-bound complex. To address the heterogeneity observed in the LMNG detergent-solubilized protein, specifically the co-existence of monomeric and dimeric species, we reconstituted purified SLC37A4 into lipid nanodiscs. This approach yielded a highly monodisperse sample, which was then incubated with the inhibitor (S1 Fig). Subsequent 2D classification and heterogeneous refinement confirmed that the SLC37A4-CHA complex exists as a homogeneous monomer. Consequently, we were able to determine the structure of the inhibitor-bound complex to a resolution of 3.3 Å (S7 Fig and Table 1). In contrast to the apo and G6P-bound structures, the CHA-bound structure adopts an inward-facing conformation. Notably, the cytosolic loop between TM6 and TM7, which was highly flexible and unresolved in the apo state, is well-resolved in this inhibitor-bound structure (Fig 3A). This state is defined by the tight closure of the gate on the ER lumen side, which prevents access from the luminal compartment (Fig 3A–3C). This closure is maintained by specific interactions between the NTD and CTD. Key stabilizing features include a salt bridge between D47 on TM2 and K389 on TM11 (Fig 3B and 3C). In addition, the bottom of the transporter is sealed by hydrogen bonds between K46 on TM2 and A388 on TM11, and between T157 on TM5 and S263 on TM8. Surface representation confirms that these residues create a tightly sealed interface, effectively locking the ER luminal gate. Structural basis of inhibition of SLC37A4 by CHA. (A) Overall structure of CHA-bound SLC37A4 shown as a cylindrical cartoon in the cytosol facing conformation. The N-terminal domain NTD is in yellow and the C-terminal domain CTD is in cyan. The cytosolic loop connecting the NTD and CTD is resolved in this structure. The bound inhibitor CHA is shown in magenta. (B) View of the NTD–CTD interface from the ER-lumen side along the membrane normal, highlighting polar and charged residues at the interdomain interface, including K46, D47, T157 in the NTD and S263, A388 and K389 in the CTD. (C) Surface representation of SLC37A4 in the same orientation as in b, showing the interdomain interface patch formed by T157, K46 and D47 in the NTD and S263, A388 and K389 in the CTD. (D) View of SLC37A4 from the cytosolic side along the membrane normal, showing the CHA was trapped at the interface of NTD and CTD. (E) Close-up view of the CHA-binding pocket, highlighting residues that form hydrophobic interactions with CHA, including W118, F134, W138 and G135 from the NTD and N354, G350, V351, H366 and V369 from the CTD. (F) Cryo-EM density of the bound CHA molecule, with a contour level of 8σ. (G) Two-dimensional schematic of the CHA-binding site, illustrating hydrophobic contacts and van der Waals interactions between CHA and surrounding residues G135, F134, W138, W118, N354, G350, V351, H366, V369 and G370. (H) Structural comparison of the apo (gray) and CHA-bound (yellow/cyan) SLC37A4 structures, viewed from the membrane plane (left), from the cytosol (middle), and separated into NTD and CTD (right), illustrating that CHA-binding induces a rigid-body rotation between the two domains without major intra-domain rearrangement. In this inward-facing conformation, a clear ligand-like density is observed on the cytosolic side at the NTD–CTD interface, which can be well fitted with a CHA molecule. CHA occupies a cavity near the cytosolic entrance at this interface, wedged between TM4–TM5 of the NTD and TM8–TM10–TM11 of the CTD (Fig 3D–3G). The inhibitor is surrounded by residues that engage in predominantly hydrophobic, van der Waals, and aromatic interactions, including W118, F134, W138, and G135 from the NTD, and V351, N354, H366, V369, and G370 from the CTD. Together, these residues form an extensive hydrophobic and aromatic interaction network with CHA, creating a non-polar pocket that matches the shape of CHA and explaining its high affinity and ability to stabilize the inward-facing conformation. Compared with the apo structure, which is in an outward-open conformation facing the ER lumen, the CHA-bound structure is cytosol-facing (Fig 3H, left). Overlay of the CHA-bound and apo structures shows that the NTD and CTD themselves undergo no significant conformational changes within each domain (Fig 3H, right). Instead, the two domains move largely as rigid bodies relative to one another during the transition between ER lumen-facing and cytosol-facing conformations (Fig 3H). This is consistent with the classic rocker switch mechanism of MFS transporters [17–19]. Conformational comparison reveals a putative G6P translocation tunnel in SLC37A4 Although we lack an experimental structure of inward-facing SLC37A4 bound to G6P, the competitive inhibitor CHA captures the transporter in a distinct inward-facing state. We reasoned that the structure obtained by manually removing CHA serves as a plausible candidate representing the conformation primed for G6P loading from the cytosol. Consequently, we utilized this in silico CHA-removed model to characterize the potential G6P transport pathway using the MOLEonline server [20]. Notably, with the ER luminal gate sealed in the inward-open state, K64 sits at the cytosolic entrance of the cavity rather than at its base, whereas R28, K29 and K240 occupy the base of the cavity. These three residues lie within 5–6 Å of one another and form a triangular, positively charged trap for G6P engagement (Fig 4A and 4B). We propose that G6P binding to this deep pocket initiates the transport cycle by neutralizing the local positive charge. Engagement of the phosphate by R28 and K29 likely stabilizes tighter NTD–CTD contacts on the cytosolic side, favoring the formation of an occluded intermediate in which both gates are transiently closed. This ligand-stabilized closure is then coupled to the canonical MFS rocker-switch motion, driving a rigid-body rearrangement of the two helical bundles that seals the cytosolic gate and remodels the luminal side to generate an outward-facing state. Conformational transitions and mechanistic model of substrate transport and inhibition. (A) Structural models of SLC37A4 in inward-open (left) and outward-open (right) conformations viewed in the membrane plane. The N-terminal domain (NTD) and C-terminal domain (CTD) are shown as yellow and cyan cartoons, respectively; horizontal black lines indicate the approximate membrane boundaries. The cluster of basic residues in the NTD (K29, R28 and K64) and K240 in the CTD are shown as green sticks. The putative translocation pathway is depicted as a transparent surface. In the inward-open state, G6P (red sticks) binds from the cytosolic side to the NTD basic cluster, while K240 in the CTD faces the cytosolic side. In the outward-open state, reorientation of the NTD and CTD exposes the binding site to the lumen, allowing G6P release and Pi binding, as indicated by arrows. (B) Close-up views of the basic residues in the inward-open (left) and outward-open (right) conformations. Distances (Å) between side-chain nitrogen atoms are indicated by dashed lines, highlighting the compact arrangement of K29, R28 and K64 in the inward-open state and their rearrangement relative to K240 upon transition to the outward-open state. (C) The schematic illustrates the conformational transitions between the inward-open, occluded, and outward-open states. The inhibition scenario (top) shows the binding of CHA to the inward-open state, which sterically hinders the transition to the occluded state (indicated by the red cross), thereby locking the transporter. In contrast, the functional antiport cycle (bottom) depicts the exchange of substrates: G6P binds to the inward-open state, facilitating the transition to the occluded state. Subsequently, the transporter shifts to the outward-open conformation to release G6P and accommodate the binding of inorganic phosphate (Pi) for transport in the reverse direction. Key residues (R28, K29, K64 on TM 1/2 and K240 on TM 7) involved in substrate/inhibitor recognition are highlighted. In the outward-facing conformation represented by the apo and G6P-bound structures, the geometry of the basic cluster shifts and R28, K29 and K240 move apart, resulting in decreased affinity for G6P. The weakened affinity promotes G6P release into the ER lumen for subsequent hydrolysis by glucose-6-phosphatase. Meanwhile, the electropositive cavity is poised to bind Pi in the ER lumen, likely engaging the same basic residues, which in turn stabilizes the return transition back toward an inward-open state. Pi release to the cytosol would complete the exchange and reset the pocket for another round of G6P/Pi exchange. Discussion In this study, we determined high-resolution cryo-EM structures of human SLC37A4 in apo, G6P-bound and CHA-bound states. Based on these structural snapshots together with our thermostability data, we propose a stepwise model for the G6P/Pi exchange mechanism (Fig 4C). The cycle likely begins from an inward-open conformation in which the basic cluster is arranged to favor high-affinity G6P binding from the cytosol. Substrate engagement is expected to promote compaction of the cytosolic cavity and formation of an occluded intermediate, in which both gates are transiently closed. Transition from this occluded state to an outward-facing conformation then proceeds through the canonical rocker-switch motion characteristic of Major Facilitator Superfamily transporters, reorienting the same electropositive cavity toward the ER lumen. In the outward-facing state, subtle rearrangements of the basic residues would lower G6P affinity, promoting its release for hydrolysis by glucose-6-phosphatase, while leaving the cavity primed for luminal Pi binding. Engagement of Pi would favor the reverse transition back toward the inward-open state, completing the exchange and resetting the transporter for another cycle. Our inhibitor-bound structure illustrates how these conformational changes can be selectively interrupted. CHA stabilizes an inward-facing state that remains competent for cytosolic access yet is conformationally trapped and unable to progress toward the occluded or outward-facing configurations required for transport (Fig 4C). Rather than simply competing with G6P at the same coordination site, CHA engages an adjacent hydrophobic–aromatic pocket at the cytosolic entrance and locks inter-domain contacts. This mode of inhibition reveals a druggable site that could be exploited to modulate G6P flux. To date, 54 pathogenic mutations have been reported in SLC37A4 [9]. By leveraging the structural roles identified here, these known pathogenic missense mutations in GSD-Ib patients can be categorized into three distinct classes. First, substrate recognition is impaired by variants such as R28C/H, K29Q, K64Q, and K240Q, which compromise the positively charged binding cavity (Fig 2E), or by Y60C and F237S, which abolish essential hydrophobic interactions stabilizing the sugar moiety (Fig 2B and 2F). This interpretation is supported by thermostability assays showing that mutations at these key coordinating residues (including R28, K29, Y60, K64, and K240) significantly reduce G6P-induced thermal shifts relative to the wild type (Fig 2G). Furthermore, these structural and thermostability defects directly translate to a severe loss of transport function, as demonstrated by the marked reduction in [13C6]G6P uptake for these mutants (Fig 2H). Second, the outward-open conformation is destabilized by mutations including D72N, T364M, R126C, T354K, T136M, and D285N, which break critical salt bridges and hydrogen bonds locking the NTD and CTD (Fig 2D). Third, the inward-facing state is compromised by variants such as D47N, K46E, K389E, A388P, T157I, and S263P, which prevent tight sealing of the ER luminal gate (Fig 3B and 3C). The remaining unmapped mutations likely impair overall structural integrity and folding and will require further investigation; together, these mechanistic classes provide a clear molecular rationale for the loss of function observed in patients. During the preparation of this manuscript, independent studies describing SLC37A4 structures in various conformational states were published [21,22]. Our models exhibit remarkable convergence with these external datasets; notably, the overall structure of our SLC37A4-G6P complex is highly similar to those from the two previously published studies (S9A and S9B Fig), and the global architectures and the specific binding mode of CHA are virtually identical across all studies (S8 Fig). In contrast to this conserved inhibitor binding, the precise coordination of G6P varies considerably among the models (S9C Fig). Interestingly, while the position of the H366 side chain remains largely unchanged across all three structures, its involvement in substrate binding differs dramatically. In our structure (SLC37A4-G6P), the phosphate group interacts with K64 and is close to Y60, but the glucose moiety points away, leaving H366 at a distance of 10.7 Å with no direct interaction (S9C Fig, left). Conversely, in PDB 9W1P, the substrate appears inverted, with the glucose ring forming close contacts (2.5–2.8 Å) with Y60, K64, and H366 (S9C Fig, middle). Meanwhile, in PDB 9KVV, the phosphate group remains near Y60 and K64 (similar to our model), but the glucose moiety is angled upwards to form a 3.3 Å interaction with H366 (S9C Fig, right). Because G6P in our structure lacks this additional coordination from H366, it exhibits a looser binding mode involving fewer overall protein contacts. We interpret this loosely bound G6P in the outward-open conformation as representing a distinct intermediate state along the transport cycle, specifically capturing a transient moment of G6P release. Although the exact cause is unclear, subtle differences in sample preparation or lipid environments likely trapped these distinct conformational snapshots. Ultimately, despite these local variations in substrate coordination, the high consistency in overall architecture across independent investigations serves as a powerful cross-validation of our findings. This collective agreement establishes a definitive structural framework for SLC37A4, providing a highly reliable foundation for interpreting disease-associated mutations and guiding rational drug design for glycogen storage disease type Ib. Materials and methods Cloning, protein expression and purification The cDNA encoding full length SLC37A4 was cloned into the pCAG vector with a C-terminal 3× Flag tag; all mutants were generated via standard PCR-based mutagenesis. For protein expression, HEK293F cells were maintained in suspension culture using SMM293-TII medium (Sino Biological) at 37°C under 8% CO2. When cell density reached 2 × 106 cells/mL, the cultures were transfected with plasmid premixed with PEI at a 1:3 mass ratio. Cells were harvested by centrifugation at 2,000g 48 h post-transfection. The cell pellets were flash-frozen in liquid nitrogen and stored at −80 °C until further use. All purification steps were performed at 4 ℃ or on ice. Cell pellets were thawed on ice-water bath and resuspended in Buffer A (25 mM HEPES pH 7.5, 150 mM NaCl, protease inhibitor cocktail containing 0.8 μM pepstatin A, 2 μM leupeptin, 2 μM aprotinin) and lysed by sonication on ice (10 s pulses, 20 s intervals, 30% amplitude). Membrane fractions were isolated by ultracentrifugation at 158,600g for 1 h. The membrane pellets were solubilized in Buffer B (25 mM HEPES pH 7.5, 150 mM NaCl, 1% (w/v) LMNG and 0.1% (w/v) cholesteryl hemisuccinate (CHS)). The insoluble material was removed by ultracentrifugation at 158,600g for 1 h. The clarified supernatant was incubated with anti-FLAG affinity resin (Smart-Lifesciences) for 1 hr. The resin was washed with 10 column volumes (CV) of Buffer C (25 mM HEPES pH 7.5, 150 mM NaCl, 0.005% [w/v] LMNG, 0.0005% [w/v] CHS). The proteins were eluted by Buffer C supplemented with 0.25 mg/mL 3× FLAG peptide (Sangon). The eluate was concentrated and further purified by gel filtration using Superdex 200 Increase 10/300 GL column (Cytiva) pre-equilibrated with Buffer D (25 mM HEPES pH 7.5, 150 mM NaCl, 0.005% LMNG, 0.0005% CHS). Peak fractions were collected and concentrated to 10–15 mg/mL for cryo-EM grid preparation. For SLC37A4 nanodisc, MSP protein and lipid extract mixture were added to the FLAG resin and incubated overnight at 4 ℃. Detergent was removed by biobeads, protein was then eluted and further purified with gel filtration using Superdex 200 pre-equilibrated with Buffer E (25 mM HEPES pH 7.5, 150 mM NaCl). In parallel, an SLC37A4–GFP fusion construct was cloned and purified using the same expression and purification pipeline, and used for thermostability assays. Cryo-EM grid preparation For cryo-EM sample preparation, freshly purified SLC37A4 at a concentration of 10–15 mg/mL was applied to glow-discharged UltrAufoil R1.2/1.3 Au 300-mesh holey carbon grids. For the ligand-bound samples, the protein was incubated with 100 mM G6P (for SLC37A4–G6P) or 10 mM CHA (for SLC37A4–CHA) for 1 hour on ice before grid preparation. Aliquots of 3 μl of sample were applied to the grids in a Vitrobot Mark IV (Thermo Fisher Scientific) operating at 4 °C and 100% relative humidity, blotted for 3.5 s with a blot force of 1, and rapidly plunge frozen into liquid ethane cooled by liquid nitrogen. Frozen grids were stored in liquid nitrogen until data collection. Cryo-EM data processing and structure refinement For SLC37A4 apo data set, the Cryo-EM data were collected on Titan Krios microscope equipped with Falcon 4 camera. Motion correction was performed with patch motion correction in CryoSPARC to correct beam-induced motion [23]. Following motion correction, the contrast transfer function of micrographs was estimated. Micrographs with CTF fit resolution worse than 4 Å were discarded. Initial particle picking was performed using blob pick with particle diameter of 80–120 Å. These particles were subjected to multiple rounds of 2D classification to generate high-quality 2D templates with visible secondary structure feature. These 2D class averages were used for template-based particle picking. To maximize the recovery of high-quality particles, the selected particles were used to train a convolutional neural network model using Topaz, which then picked additional particles missed by blob pick and template pick [24]. Particles from blob pick, template pick and Topaz were merged and duplicates were removed. The merged particles set underwent multiple rounds of 2D classification, only classes with clear secondary structure were kept for ab initio reconstruction and heterogeneous refinement. Given that SLC37A4 is a small membrane protein lacking a large soluble domain, a seeding strategy was employed in the heterogeneous refinement to enlarge particle pool [25]. Good particles were selected for NU-refinement, yielding a map with a resolution of 3.0 Å. The particle coordinates were imported into Relion and the particles were re-extracted [26,27]. A final round of 3D auto-refinement was performed, followed by Bayesian polishing and CTF refinement, which improved the overall resolution to 2.8 Å. The same data processing strategy was applied to both the SLC37A-G6P and SLC37A-CHA datasets. For model building, an initial structural model of SLC37A4 was obtained via AlphaFold prediction [28]. The predicted model was rigid-body fitted into the cryo-EM reconstruction map using UCSF chimera [29]. Regions of the predicted model that did not agree with the experimental density were manually rebuilt using COOT [30]. The model was finalized through iterative cycles of manual adjustment and automatic real-space refinement using Phenix (phenix.real_space_refine, applying secondary structure and geometry restraints) [31]. All representations of cryo-EM density and structural models were prepared with Chimera [29] and PyMOL [32]. A summary of data collection, processing, and model-refinement statistics for all three data sets is provided in Table 1. Thermal shift analysis For thermal shift analysis of SLC37A4, a GFP-based assay was employed in which GFP was fused to the C-terminus of SLC37A4. The SLC37A4–GFP fusion proteins (wild-type and mutants) were purified using the same procedure described above. The GFP thermal shift assays were carried out according to previous studies [33,34]. Purified GFP-tagged SLC37A4 was diluted to 0.6 µM in assay buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1% (w/v) LMNG) in a final volume of 90 µl per well and incubated in the presence or absence of 10 mM G6P for 10 min. After incubation, 10 µL of 10% (w/v) β-n-octyl-β-d-glucopyranoside was added to each well. Samples were then heated to 10, 20, 30, 40, 50, 60, 70, or 80 ℃ for 10 min, centrifuged to remove aggregated protein, and the supernatant was transferred to a black 96-well plate. Soluble GFP fluorescence was measured on a plate reader (excitation 488 nm, emission 512 nm), and values were normalized to the signal at the lowest temperature condition. To generate thermal transition curves, the fluorescence data were normalized by setting the highest and lowest data points to 100% and 0%, respectively. The normalized fluorescence values were plotted against temperature, and apparent melting temperatures (Tm) for each condition were determined by fitting the data to a sigmoidal four-parameter logistic function using GraphPad Prism. To evaluate whether the mutated residues affected G6P binding, the shift in melting temperature (ΔTm) was calculated for each protein by subtracting the Tm of the apo state from the Tm of the G6P-incubated state. [¹³C]G6P uptake assay in G6PT-expressing cells For the cellular G6P uptake assay, the assay was preformed based on previously described method [22] with minor modification. HEK293F cell were transfected with SLC37A4 plasmids (WT or mutants) premixed with PEI at 1:3 mass ratio as described in the protein purification section. Forty-eight hours post-transfection, cells were pelleted by centrifugation at 1,000g for 5 min, washed once with Wash Buffer A1 (1× Hanks’ Balanced Salt Solution [HBSS, Gibco] supplemented with 2% FBS), and permeabilized with Permeabilization Buffer A2 (1× HBSS supplemented with 10 µM digitonin) at 37 °C for 10 min. This low concentration of digitonin was utilized to selectively permeabilize the cholesterol-rich plasma membrane while maintaining the integrity of the ER membrane. Following permeabilization, cells were washed with 1× HBSS twice to remove residual buffer. Uptake was initiated by adding a 1:1 molar mixture of [¹³C6]G6P and unlabeled G6P (MedChemExpress) to a final concentration of 1 mM. After a 10-min incubation at 37 °C, the reaction was quenched by washing the cells twice with 500 µL of ice-cold 1× HBSS. Intracellular [¹³C6]G6P was extracted using 200 µL of pre-chilled methanol: acetonitrile (2:1, v/v), followed by ultrasonication at 4 °C for 10 min. The extract was centrifuged at 12,000 rpm for 20 min at 4 °C, and 150 µL of the resulting supernatant was transferred to a fresh tube and lyophilized for subsequent quantitative LC–MS analysis. The remaining cell pellet was lysed in 400 µL of 0.1 M KOH, and the protein concentration was determined using a BCA protein assay kit (Yeasen). [¹³C6]G6P uptake levels were normalized to the corresponding total protein content. All experiments were performed at least in triplicate, and data were analyzed using nonlinear regression in Prism 8.0.1 (GraphPad Software). Quantification of [¹³C6]G6P by LC–MS Lyophilized [¹³C6]G6P samples were quantified using liquid chromatography–mass spectrometry (LC–MS). Samples were resolved on an Agilent 1290 Infinity II-6495B UPLC–MS system equipped with an ACQUITY UPLC BEH Amide column (2.1 mm × 100 mm, 1.7 μm). The mobile phase consisted of acetonitrile:water (9:1, v/v) supplemented with 15 mM ammonium acetate and 0.3% ammonium hydroxide. Detection was performed in negative electrospray ionization mode (ESI−), and [¹³C6]G6P was monitored via multiple reaction monitoring (MRM) at m/z 264.9. Data acquisition and analysis were performed using MassHunter Workstation Data Acquisition (version 10.0 SR1) and Quantitative Analysis (version 10.0) software (Agilent Technologies), respectively. Compound identity was confirmed by matching retention times and MRM transitions to a reference standard. Quantification was achieved using an external calibration curve, with final concentrations calculated based on sample volume. Western blot HEK293F cells (1 × 106 cells/mL) expressing empty vector, wild-type G6PT, or mutants were harvested, washed with PBS, and lysed in 400 μL buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1% [w/v] DDM, 0.1% [w/v] CHS, 2 µM pepstatin A, 4.2 µM leupeptin, and 0.8 µM aprotinin). After 1.5 h at 4 °C, lysates were cleared by ultracentrifugation. Solubilized proteins were resolved by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for 1 h at room temperature in TBST containing 5% nonfat milk and then incubated overnight at 4 °C with rabbit monoclonal anti-Flag antibody (1:3,000; Cell Signaling Technology, Cat#14793) and anti-calnexin antibody (1:1,000; Cell Signaling Technology, Cat#2679S), which served as an internal loading control. After washing, membranes were incubated with HRP-conjugated secondary antibodies for 45 min at room temperature. Protein bands were visualized by chemiluminescence using an iBright FL1500 imaging system. Supporting information Purification and reconstitution of human SLC37A4. (A) Size-exclusion chromatography (SEC) profile and SDS-PAGE of SLC37A4 purified in LMNG detergent. (B) SEC profile and SDS-PAGE of SLC37A4 reconstituted into MSP1E1D1 nanodiscs. (TIF) Cryo-EM data processing and validation of human SLC37A4-apo. (A) Workflow of cryo-EM data processing, including representative micrographs, 2D class averages showing dimers and monomers, 3D classification, and refinement steps leading to the final reconstruction. (B) Angular distribution of particles used in the final reconstruction. (C) Fourier shell correlation (FSC) curves indicating the overall resolution at 0.143 cutoff (blue) and map-to-model correlation (red). (D) Local resolution map showing resolution distribution across the density map. (E) Representative cryo-EM densities for transmembrane helices (TM1–TM12) with the atomic model fitted. (TIF) Cryo-EM data processing and validation of human SLC37A4-G6P. (A) Workflow of cryo-EM data processing, including representative micrographs, 2D class averages showing dimers and monomers, 3D classification, and refinement steps leading to the final reconstruction. (B) Angular distribution of particles used in the final reconstruction. (C) Fourier shell correlation (FSC) curves indicating the overall resolution at 0.143 cutoff (blue) and map-to-model correlation (red). (D) Local resolution map showing resolution distribution across the density map. (E) Representative cryo-EM densities for transmembrane helices (TM1–TM12) with the atomic model fitted. (TIF) Cryo-EM density around the G6P pocket. Overlay of the SLC37A4–G6P (blue) and apo (orange) maps, both contoured at 3σ. The comparison reveals additional density for the bound G6P molecule near residues Y60, K64, and F237. (TIF) Thermal transition curves of wild-type and mutant SLC37A4. (A–H) GFP-based thermal shift assays for wild-type (WT) SLC37A4 (A) and mutants R28A (B), R28C (C), R28H (D), K29A (E), Y60A (F), K64A (G), and K240A (H). The normalized fluorescence intensity (FI) signal is plotted as a function of temperature. Assays were performed in the absence (gray circles) or presence (red triangles) of 10 mM glucose-6-phosphate (G6P). Data were from at least triplicates. The calculated apparent melting temperatures (Tm) for each individual replicate are indicated in each panel. The underlying data for this figure can be found in S1 Data. (TIF) Protein expression levels of SLC37A4 wild-type and mutants. Western blot analysis evaluating the expression of Flag-tagged wild-type (WT) and mutant SLC37A4 constructs (R28A, R28C, R28H, K29A, Y60A, K64A, and K240A). Calnexin was probed as a loading control. The results demonstrate that all generated mutants express at levels comparable to the WT protein, confirming that the observed reductions in transport activity are due to functional impairments rather than decreased protein stability or expression. The control lane represents the untransfected/empty vector negative control. (TIF) Cryo-EM data processing and validation of human SLC37A4-CHA. (A) Workflow of cryo-EM data processing, including representative micrographs, 2D class averages showing dimers and monomers, 3D classification, and refinement steps leading to the final reconstruction. (B) Angular distribution of particles used in the final reconstruction. (C) Fourier shell correlation (FSC) curves indicating the overall resolution at 0.143 cutoff (blue) and map-to-model correlation (red). (D) Local resolution map showing resolution distribution across the density map. (E) Representative cryo-EM densities for transmembrane helices (TM1–TM12) with the atomic model fitted. (TIF) Structural comparison of the inward-facing SLC37A4–CHA complex. Alignment of our SLC37A4–CHA structure (cyan) with a previously reported CHA-bound structure (PDB 9KV0, magenta). Orthogonal views highlight the conserved inward-facing architecture and overlapping CHA-binding sites. (TIF) Structural comparison of G6P-bound SLC37A4. (A, B) Orthogonal views aligning our SLC37A4–G6P structure (cyan) with previously reported G6P-bound models (PDB 9W1P, magenta; PDB 9KVV, green). (C) Detailed comparison of the G6P binding pockets across the three structures. Key interacting residues (Y60, K64, and H366) and the G6P ligand are shown as sticks, with measurement distances indicated in angstroms (Å). (TIF) Original uncropped and minimally adjusted gel and blot images corresponding to. S1A, S1B, and S6 Figs. The upper-left and upper-right panels correspond to S1A and S1B Fig, respectively; the lower panels correspond to S6 Fig. Dashed boxes indicate the regions cropped and displayed in the corresponding Supporting information panels. (DOCX) Underlying numerical data for Figs 2G, 2H, and S5. This file contains individual replicate values, calculated means, standard deviations, and replicate numbers used to generate the plotted data. Replicate values are arranged vertically, and summary tables indicate how the plotted mean ± s.d. values were derived. (XLSX) 6 Jan 2026 Dear Dr Wei, Thank you for submitting your manuscript entitled "Structural insight into substrate recognition and inhibition of human glucose 6-phosphate transporter SLC37A4" for consideration as a Short Report by PLOS Biology. Please accept my sincere apologies for the delay in getting back to you due to the closure of the editorial office during the recent holiday period. Your manuscript has now been evaluated by the PLOS Biology editorial staff, as well as by an academic editor with relevant expertise, and I am writing to let you know that we would like to send your submission out for external peer review under our complementary research policy. However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire. Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. After your manuscript has passed the checks it will be sent out for review. To provide the metadata for your submission, please Login to Editorial Manager (https://www.editorialmanager.com/pbiology) within two working days, i.e. by Jan 08 2026 11:59PM. If your manuscript has been previously peer-reviewed at another journal, PLOS Biology is willing to work with those reviews in order to avoid re-starting the process. Submission of the previous reviews is entirely optional and our ability to use them effectively will depend on the willingness of the previous journal to confirm the content of the reports and share the reviewer identities. Please note that we reserve the right to invite additional reviewers if we consider that additional/independent reviewers are needed, although we aim to avoid this as far as possible. In our experience, working with previous reviews does save time. If you would like us to consider previous reviewer reports, please edit your cover letter to let us know and include the name of the journal where the work was previously considered and the manuscript ID it was given. In addition, please upload a response to the reviews as a 'Prior Peer Review' file type, which should include the reports in full and a point-by-point reply detailing how you have or plan to address the reviewers' concerns. During the process of completing your manuscript submission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit http://journals.plos.org/plosbiology/s/preprints for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF. Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission. Kind regards, Richard Richard Hodge, PhD Senior Editor, PLOS Biology rhodge@plos.org PLOS Empowering researchers to transform science Carlyle House, Carlyle Road, Cambridge, CB4 3DN, United Kingdom California (U.S.) corporation #C2354500, based in San Francisco 4 Feb 2026 Dear Dr Wei, Thank you for your patience while your manuscript "Structural insight into substrate recognition and inhibition of human glucose 6-phosphate transporter SLC37A4" was peer-reviewed at PLOS Biology. Please accept my apologies for the delays that you have experienced during the peer review process. Your manuscript has now been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by two independent reviewers. In light of the reviews, which you will find at the end of this email, we would like to invite you to revise the work to thoroughly address the reviewers' reports. As you will see below, the reviewers think the glucose-6-phosphate transporter structure is interesting and of high-quality, but they raise overlapping concerns with the lack of mutational validation and further mechanistic insight in the manuscript. Specifically, Reviewer #1 notes that transport assays should be provided to strengthen the functional relevance of the work and Reviewer #2 asks that thermal shift assay data for each mutant are provided, as well as providing a comparison with recently published G6PT structures. Given the extent of revision needed, we cannot make a decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is likely to be sent for further evaluation by all or a subset of the reviewers. In addition to these revisions, you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests shortly. We expect to receive your revised manuscript within 3 months. Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may withdraw it. **IMPORTANT - SUBMITTING YOUR REVISION** Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript: 1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript. *NOTE: In your point-by-point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point. You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response. 2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Revised Article with Changes Highlighted" file type. *Re-submission Checklist* When you are ready to resubmit your revised manuscript, please refer to this re-submission checklist: https://plos.io/Biology_Checklist To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record. Please make sure to read the following important policies and guidelines while preparing your revision: *Published Peer Review* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details: https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/ *PLOS Data Policy* Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5 *Blot and Gel Data Policy* We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements *Protocols deposition* To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments. Best regards, Richard Richard Hodge, PhD Senior Editor, PLOS Biology rhodge@plos.org ------------------------------------ REVIEWS: Reviewer #1: In this work, the authors report the cryo-EM structures of human SLC37A4 in apo, G6P-bound, and CHA-bound states, providing an important structural framework for substrate recognition and inhibition. The manuscript is well written. Although a few highly related studies have been published recently, considering the scope of PLOS Biology, this work remains valuable and should be suitable for publication if the following concerns are properly addressed. 1. Transport assay As SLC37A4 is a G6P/Pi exchanger, the mechanistic conclusions would be substantially strengthened by adding a transport assay (e.g., using reconstituted proteoliposomes or a cellular transport assay). Some mutational analysis using a transport assay should be performed in the revision. 2. Terminology for CHA as "allosteric" The authors describe CHA as binding to an "allosteric" site. However, the structures show that the CHA-interacting region partially overlaps with the G6P-binding region. Therefore, it is unclear whether it is appropriate to refer to this site as allosteric. Thus, if the authors continue to use the term "allosteric," please provide a more detailed explanation and justification. Otherwise, please refrain from using "allosteric". 3 Typos Page 17, Line 16 (Data Availability) "SCL37A4" should be corrected as "SLC37A4". "EMD-64869" should be corrected as "EMD-67869". Supplementary Figure 5. In panel d, "Y64" should be corrected as "Y60". In panel e, "PDB 9KVO" should be corrected as "PDB 9KV0". Reviewer #2: In this manuscript, Li et al. report cryo-EM structures of the human glucose-6-phosphate transporter (G6PT/SLC37A4) in the apo and G6P-bound states, as well as in complex with the allosteric inhibitor chlorogenic acid (CHA). These structures capture the transporter in both inward- and outward-facing conformations characteristic of Major Facilitator Superfamily transporters, allowing them to draw conclusions about the conformational changes occurring during the transport cycle. Overall, the study provides new insights into the structure, function, and conformational dynamics of the SLC37 family. The structural work is of high quality, but I have several comments that may help to further strengthen the manuscript. 1.) Modeling of the cytoplasmic loop connecting the N- and C-bundle The authors did not specify which portion of the cytoplasmic loop connecting TM6 and TM7 was modeled. A clear description and labeling in the figures would be helpful. Are there any disease related mutations located? 2.) Comments to figures - all figures (main plus supplementary) illustrating EM densities require a statement on the shown contour level - label termini (at least in the first figure); loops or parts not modelled should be shown in dashed lines - enlarge the density for G6P in figure 2 and show from at least two different orientations - highlight EM density for CHA in figure 3 (not only in supplementary figure) 3.) Thermal shift data There is no information on the concentrations of the substrates used for this assay and overall the assay is described quite poorly. What has been done? How were the data analyzed? I recommend showing at least as a supplementary figure the thermal transitions curves for each mutant (+/- substrate) including the fit to a two state unfolding model. Comparing the thermal shift at a single concentration can often also be quite misleading, since the absolute shift is not always a measure of affinity. I recommend to measure a concentration dependent shift for the different mutants and determine apparent Kds. This allows a much better comparison of the mutants. A bit puzzling are the data on the K64A mutant - although identified as crucial in coordinating the substrate, the mutant obviously still binds almost as wild type. Do you have any idea or speculation as to why this is the case? 4.) Comparison to recently published G6PT structures (PMID: 41136424 and 41225049) and related work. The current manuscript lacks functional transport data to directly validate or challenge the structural interpretations. However, recent studies on SLC37A4 have already reported extensive biochemical and transport data (on substrates, inhibitors and mutational effects) that could be integrated and discussed in the context of the presented structures. This structure-function analysis would strengthen the manuscript. The authors begin to compare their structures with those from recent publications (Supplementary Figure 5) and state in the Discussion that the results are largely similar. Nevertheless, closer inspection of the G6P-bound structures reveals notable differences that should be discussed in more detail. In particular, the authors should clarify which structural features are conserved across studies and where do they differ. A more systematic comparison addressing shared and distinct features across the available G6PT structures would help readers better understand how the present work extends, refines, or revises the existing structural framework for SLC37A4. Minor points: Supplementary Figures 2-4 C: should read 'model' Supplementary Figures 2-4 D: unit Å is missing 13 Apr 2026 Submitted filename: response-041026.docx 13 May 2026 Dear Dr Wei, Thank you for your patience while we considered your revised manuscript entitled "Structural insight into substrate recognition and inhibition of human glucose 6-phosphate transporter SLC37A4" for publication as a Short Report at PLOS Biology. This revised version of your manuscript has been evaluated by the PLOS Biology editors, the Academic Editor and the two original reviewers. Based on the reviews (attached below), we are likely to accept this manuscript for publication provided you document better the cellular transport studies in the methods, as requested by the Academic Editor, and that you reduce the main figures to a total of four to comply with the requirements of our Short Reports. Please also make sure to address the policy-related requests stated below my signature. In addition, we would like you to consider a suggestion to improve the title: “Structural basis for substrate recognition and inhibition of the human glucose 6-phosphate transporter SLC37A4” As you address these items, please take this last chance to review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the cover letter that accompanies your revised manuscript. In addition to these revisions, you may need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests shortly. If you do not receive a separate email within a few days, please assume that checks have been completed, and no additional changes are required. We expect to receive your revised manuscript within two weeks. To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include the following: - a cover letter that should detail your responses to any editorial requests, if applicable, and whether changes have been made to the reference list - a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable, if not applicable please do not delete your existing 'Response to Reviewers' file.) - a track-changes file indicating any changes that you have made to the manuscript. NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines: https://journals.plos.org/plosbiology/s/supporting-information *Published Peer Review History* Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details: https://plos.org/published-peer-review-history/ *Press* Should you, your institution's press office or the journal office choose to press release your paper, please ensure you have opted out of Early Article Posting on the submission form. We ask that you notify us as soon as possible if you or your institution is planning to press release the article. *Protocols deposition* To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols Please do not hesitate to contact me should you have any questions. Sincerely, Ines -- Ines Alvarez-Garcia, PhD Senior Editor PLOS Biology ialvarez-garcia@plos.org on behalf of Richard Hodge, PhD Senior Editor PLOS Biology rhodge@plos.org ------------------------------------------------------------------------ DATA POLICY: You may be aware of the PLOS Data Policy, which requires that all data be made available without restriction: http://journals.plos.org/plosbiology/s/data-availability. For more information, please also see this editorial: http://dx.doi.org/10.1371/journal.pbio.1001797 Note that we do not require all raw data. Rather, we ask that all individual quantitative observations that underlie the data summarized in the figures and results of your paper be made available in one of the following forms: 1) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Supporting Information' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore). 2) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication. Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels as they are essential for readers to assess your analysis and to reproduce it: Fig. 2G-H and Fig. S5A-H NOTE: the numerical data provided should include all replicates AND the way in which the plotted mean and errors were derived (it should not present only the mean/average values). Please also ensure that figure legends in your manuscript include information on WHERE THE UNDERLYING DATA CAN BE FOUND, and ensure your supplemental data file/s has a legend. Please ensure that your Data Statement in the submission system accurately describes where your data can be found. **In addition, please make the structures publicly available at this stage. ------------------------------------------------------------------------ CODE POLICY Per journal policy, if you have generated any custom code during the course of this investigation, please make it available without restrictions. Please ensure that the code is sufficiently well documented and reusable, and that your Data Statement in the Editorial Manager submission system accurately describes where your code can be found. More information on our Code Policy, what and how to share can be found here: https://journals.plos.org/plosbiology/s/code-availability Please note that we cannot accept sole deposition of code in GitHub, as this could be changed after publication. However, you can archive this version of your publicly available GitHub code to Zenodo. Once you do this, it will generate a DOI number, which you will need to provide in the Data Accessibility Statement (you are welcome to also provide the GitHub access information). See the process for doing this here: https://docs.github.com/en/repositories/archiving-a-github-repository/referencing-and-citing-content ------------------------------------------------------------------------- BLOT AND GEL REPORTING REQUIREMENTS: We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare and upload them now. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements ------------------------------------------------------------------------ Reviewers' comments Reviewer #1: The authors addressed all of my concerns. Reviewer #2: The authors have substantially revised the manuscript and have addressed all of my previous comments and concerns. Although the revisions required a considerable amount of work, I feel the effort was worthwhile. The implemented functional data and the comparison with the previously published structures nicely complement this work. I recommend the manuscript for publication. 18 May 2026 Dear Dr Wei, On behalf of my colleagues and the Academic Editor, Raimund Dutzler, I am pleased to say that we can accept your manuscript for publication, provided you address any remaining formatting and reporting issues. These will be detailed in an email you should receive within 2-3 business days from our colleagues in the journal operations team; no action is required from you until then. Please note that we will not be able to formally accept your manuscript and schedule it for publication until you have completed any requested changes. Please take a minute to log into Editorial Manager at http://www.editorialmanager.com/pbiology/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. PRESS We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have previously opted in to the early version process, we ask that you notify us immediately of any press plans so that we may opt out on your behalf. We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/. Thank you again for choosing PLOS Biology for publication and supporting Open Access publishing. We look forward to publishing your study. Best wishes, Richard Richard Hodge, PhD Senior Editor, PLOS Biology rhodge@plos.org PLOS Empowering researchers to transform science Carlyle House, Carlyle Road, Cambridge, CB4 3DN, United Kingdom California (U.S.) corporation #C2354500, based in San Francisco